Literature DB >> 26456171

Identification, design and synthesis of tubulin-derived peptides as novel hyaluronan mimetic ligands for the receptor for hyaluronan-mediated motility (RHAMM/HMMR).

Kenneth Virgel N Esguerra1, Cornelia Tolg, Natalia Akentieva, Matthew Price, Choi-Fong Cho, John D Lewis, James B McCarthy, Eva A Turley, Leonard G Luyt.   

Abstract

Fragments of the extracellular matrix component hyaluronan (HA) promote tissue inflammation, fibrosis and tumor progression. HA fragments act through HA receptors including CD44, LYVE1, TLR2, 4 and the receptor for hyaluronan mediated motility (RHAMM/HMMR). RHAMM is a multifunctional protein with both intracellular and extracellular roles in cell motility and proliferation. Extracellular RHAMM binds directly to HA fragments while intracellular RHAMM binds directly to ERK1 and tubulin. Both HA and regions of tubulin (s-tubulin) are anionic and bind to basic amino acid-rich regions in partner proteins, such as in HA and tubulin binding regions of RHAMM. We used this as a rationale for developing bioinformatics and SPR (surface plasmon resonance) based screening to identify high affinity anionic RHAMM peptide ligands. A library of 12-mer peptides was prepared based on the carboxyl terminal tail sequence of s-tubulin isoforms and assayed for their ability to bind to the HA/tubulin binding region of recombinant RHAMM using SPR. This approach resulted in the isolation of three 12-mer peptides with nanomolar affinity for RHAMM. These peptides bound selectively to RHAMM but not to CD44 or TLR2,4 and blocked RHAMM:HA interactions. Furthermore, fluorescein-peptide uptake by PC3MLN4 prostate cancer cells was blocked by RHAMM mAb but not by CD44 mAb. These peptides also reduced the ability of prostate cancer cells to degrade collagen type I. The selectivity of these novel HA peptide mimics for RHAMM suggest their potential for development as HA mimetic imaging and therapeutic agents for HA-promoted disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26456171      PMCID: PMC4721638          DOI: 10.1039/c5ib00222b

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  59 in total

Review 1.  Hyaluronan-binding proteins: tying up the giant.

Authors:  Anthony J Day; Glenn D Prestwich
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

Review 2.  Structural insight into microtubule function.

Authors:  E Nogales
Journal:  Annu Rev Biophys Biomol Struct       Date:  2001

3.  Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes.

Authors:  Mandana Veiseh; Daniel Breadner; Jenny Ma; Natalia Akentieva; Rashmin C Savani; Rene Harrison; David Mikilus; Lisa Collis; Stefan Gustafson; Ting-Yim Lee; James Koropatnick; Leonard G Luyt; Mina J Bissell; Eva A Turley
Journal:  Biomacromolecules       Date:  2011-12-12       Impact factor: 6.988

4.  Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis.

Authors:  Yi-Chieh Nancy Du; Chen-Kung Chou; David S Klimstra; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-21       Impact factor: 11.205

5.  Peptides that mimic glycosaminoglycans: high-affinity ligands for a hyaluronan binding domain.

Authors:  M R Ziebell; Z G Zhao; B Luo; Y Luo; E A Turley; G D Prestwich
Journal:  Chem Biol       Date:  2001-11

6.  Association of RHAMM with E2F1 promotes tumour cell extravasation by transcriptional up-regulation of fibronectin.

Authors:  Claudia Meier; Alf Spitschak; Kerstin Abshagen; Shailendra Gupta; Joel M Mor; Olaf Wolkenhauer; Jörg Haier; Brigitte Vollmar; Vijay Alla; Brigitte M Pützer
Journal:  J Pathol       Date:  2014-08-28       Impact factor: 7.996

7.  The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments.

Authors:  Jian-Guo Zhang; Peter E Czabotar; Antonia N Policheni; Irina Caminschi; Soo San Wan; Susie Kitsoulis; Kirsteen M Tullett; Adeline Y Robin; Rajini Brammananth; Mark F van Delft; Jinhua Lu; Lorraine A O'Reilly; Emma C Josefsson; Benjamin T Kile; Wei Jin Chin; Justine D Mintern; Maya A Olshina; Wilson Wong; Jake Baum; Mark D Wright; David C S Huang; Narla Mohandas; Ross L Coppel; Peter M Colman; Nicos A Nicola; Ken Shortman; Mireille H Lahoud
Journal:  Immunity       Date:  2012-04-05       Impact factor: 31.745

Review 8.  RHAMM and CD44 peptides-analytic tools and potential drugs.

Authors:  Eva A Turley; David Naor
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

9.  CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.

Authors:  Nicola Montgomery; Ashleigh Hill; Suzanne McFarlane; Jessica Neisen; Anthony O'Grady; Susie Conlon; Karin Jirstrom; Elaine W Kay; David J J Waugh
Journal:  Breast Cancer Res       Date:  2012-05-23       Impact factor: 6.466

Review 10.  The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression.

Authors:  Dragana Nikitovic; Katerina Kouvidi; Nikos K Karamanos; George N Tzanakakis
Journal:  Biomed Res Int       Date:  2013-09-05       Impact factor: 3.411

View more
  6 in total

1.  Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.

Authors:  S B Bahrami; C Tolg; T Peart; C Symonette; M Veiseh; J U Umoh; D W Holdsworth; J B McCarthy; L G Luyt; M J Bissell; A Yazdani; E A Turley
Journal:  Integr Biol (Camb)       Date:  2017-02-20       Impact factor: 2.192

Review 2.  Proteoglycans in Toll-like receptor responses and innate immunity.

Authors:  Stavros Garantziotis; Rashmin C Savani
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-08       Impact factor: 5.282

Review 3.  Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment.

Authors:  Eva A Turley; David K Wood; James B McCarthy
Journal:  Cancer Res       Date:  2016-04-20       Impact factor: 12.701

Review 4.  Extracellular matrix and its therapeutic potential for cancer treatment.

Authors:  Jiacheng Huang; Lele Zhang; Dalong Wan; Lin Zhou; Shusen Zheng; Shengzhang Lin; Yiting Qiao
Journal:  Signal Transduct Target Ther       Date:  2021-04-23

Review 5.  The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities.

Authors:  Josephine A Hinneh; Joanna L Gillis; Nicole L Moore; Lisa M Butler; Margaret M Centenera
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

6.  Thymosin α1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK.

Authors:  Walter Mandaliti; Ridvan Nepravishta; Francesca Pica; Paola Sinibaldi Vallebona; Enrico Garaci; Maurizio Paci
Journal:  Molecules       Date:  2017-10-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.